Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy
Pharma
Sanofi sues Sarepta over 2 gene therapy manufacturing patents
Sanofi has filed a complaint claiming that in producing Duchenne muscular dystrophy treatment Elevidys, Sarepta encroaches on two of its patents.
Kevin Dunleavy
Jul 30, 2024 5:21pm
Pfizer's DMD loss is Sarepta's gain: analysts
Jun 13, 2024 10:58am
NS Pharma's Duchenne drug Viltepso flunks confirmatory trial
May 28, 2024 11:54am
Sarepta's Elevidys off to strong start despite label restriction
Nov 2, 2023 4:21pm
FDA signs off on Santhera's muscular dystrophy drug Agamree
Oct 27, 2023 8:23am
Sarepta pawns off PRV for $102M to unidentified buyer
Jul 6, 2023 8:10am
